Citations 2
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Page, David B. , Broeckx, Glenn , Jahangir, Chowdhury Arif , Verbandt, Sara , Gupta, Rajarsi , Thagaard, Jeppe , Khiroya, Reena, Kos, Zuzana , Haab, Gabriela Acosta , Ács, Balázs , Alvarado‐Cabrero, Isabel , Baharun, Nurkhairul Bariyah, Bellolio, Enrique , Bheemaraju, Vydehi, Blenman, Kim RM, Fujimoto, Luciana Botinelly Mendonça , Bouchmaa, Najat , Burgues, Octavio, Cheang, Maggie C.U. , Ciompi, Francesco , Cooper, Lee , Coosemans, An , Corredor, Germán, Portela, Flávio Luis Dantas , Deman, Frederik , Dudgeon, Sarah , Elghazawy, Mahmoud , Ely, Scott , Fernandez‐Martín, Claudio , Fineberg, Susan , Gnjatic, Sacha , Halama, Niels , Hanna, Matthew G, Harbhajanka, Aparna , Hardas, Alexandros , Hartman, Johan , Hewitt, Stephen M. , Hida, Akira I. , Husain, Zaheed, Hytopoulos, Evangelos, Irshad, Sheeba , Janssen, Emiel A. M., Kahila, Mohamed, Kataoka, Tatsuki R. , Kawaguchi, Kosuke, Durga, Kharidehal, Khramtsov, Andrey , Kirtani, Pawan, Korski, Konstanty, Lænkholm, Anne‐Vibeke , Lang‐Schwarz, Corinna , Larsimont, Denis , Lennerz, Jochen K. , Li, Xiaoxian , Maley, Sai, Narasimhamurthy, Vidya Manur, Marks, Douglas K. , Mehrotra, Ravi , Michiels, Stefan, Mittal, Shachi , Mushtaq, Shamim , Hussain, Nighat , Papathomas, Thomas , Perera, Rashindrie , Pinard, Christopher J. , Pinto‐Cardenas, Juan Carlos , Rau, Tilman T. , Ribeiro, Joana , Salto‐Tellez, Manuel , Siziopikou, Kalliopi P. , Sotiriou, Christos, Stenzinger, Albrecht , Sughayer, Maher A. , Symmans, Fraser, Tanaka, Sunao , Taxter, Timothy , Tejpar, Sabine , Teuwen, Jonas, Thompson, E. Aubrey , Tramm, Trine , Tran, William T, Laak, Jeroen van der , Verghese, Gregory , Viale, Giuseppe , Vieth, Michael, Wahab, Noorul , Walter, Thomas , Waumans, Yannick , Wen, Hannah Y. , Yang, Wentao , Yuan, Yinyin, Bartlett, John Mark Seaverns, Loibl, Sibylle , Loi, Sherene , Salgado, Roberto , Stovgaard, Elisabeth Specht , Symmans, W. Fraser , Kahila, Mohamed M. , Gupta, Rajarsi R , Dantas Portela, Flavio Luis , Elghazawy, Mahmoud , Gonzalez-Ericsson, Paula I , Grigoriadis, Anita , Chardas, Alexandros , Hart, Steven N , Hartman, Johan , Kataoka, Tatsuki R , Rau, Tilman T , Reis-Filho, Jorge S , Rimm, David , Verghese, Gregory E , Wahab, Noorul , Gnjatic, Sacha , Broeckx, Glenn , Cheang, Maggie Chon U , Symmans, W Fraser , Lennerz, Jochen , Loi, Sherene , Acs, Balazs , Walter, Thomas , Irshad, Sheeba , McDonald, Elizabeth S. , AbdulJabbar, Khalid , Aktürk, Güray , Almeida, Jonas S. , Ardalan, Farid Azmoudeh , Badve, Sunil, Corredor, Germán , Demaria, Sandra , Fox, Stephen B. , Gallagher, William M. , Giltnane, Jennifer Margaret , González-Ericsson, Paula I. , Hart, Steven N. , Horlings, Hugo , Kawaguchi, Kosuke , Kiraz, Umay , Kodach, Liudmila L. , Kovács, Anikó , Lerousseau, Marvin , Ly, Amy , Madabhushi, Anant , Michiels, Stefan , Minhas, Fayyaz , Moore, David , Penault-Llorca, Frederique Madeleine , Pruneri, Giancarlo , Pusztai, Lajos , Rahman, Arman , Rajpoot, Nasir , Rapoport, Bernardo L. , Reis‐Filho, Jorge S. , Rimm, David L. , Vincent‐Salomon, Anne , Saltz, Joel , Sayed, Shahin , Sur, Daniel Genel , Tran, William T, Diest, P. J. van , Yuan, Yinyin , Adams, Sylvia , Bartlett, John M.S. , Denkert, Carsten , Savas, Peter Stephen
The Journal of Pathology | August 23, 2023 | Volume: 260 | Issue: 5 | Pages: 514-532
Abstract Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized method for describing or analyzing spatial immune cell data, and most reported spatial analyses are rudimentary. In this review, we provide an overview of two approaches for reporting and analyzing spatial data (raster versus vector‐based). We then provide a compendium of spatial immune cell metrics that have been reported in the literature, summarizing prognostic associations in the context of a variety of cancers. We conclude by discussing two well‐described clinical biomarkers, the breast cancer stromal tumor infiltrating lymphocytes score and the colon cancer Immunoscore, and describe investigative opportunities to improve clinical utility of these spatial biomarkers. © 2023 The Pathological Society of Great Britain and Ireland.
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
González-Ericsson, Paula I. , Stovgaard, Elisabeth Specht , Reisenbichler, Emily , Kos, Zuzana , Carter, Jodi M. , Michiels, Stefan , Quesne, John Le , Lænkholm, Anne‐Vibeke , Adam, Julien , Bartlett, John MS, Rimm, David L. , Quinn, Cecily , Cree, Ian A. , Hida, Akira I. , Haynes, Harry R. , Frahm, Isabel, Acosta‐Haab, Gabriela, Balancin, Marcelo Luiz , Bellolio, Enrique , Yang, Wentao , Kirtani, Pawan , Sugie, Tomoharu , Ehinger, Anna , Castaneda, Carlos, Kok, Marleen , McArthur, Heather L. , Siziopikou, Kalliopi P. , Fineberg, Susan , Gown, Allen M. , Viale, Giuseppe , Schnitt, Stuart J. , Pruneri, Giancarlo , Penault‐Llorca, Frederique, Hewitt, Stephen M. , Thompson, E. Aubrey , Allison, Kimberly H. , Symmans, W. Fraser , Bellizzi, Andrew M. , Brogi, Edi , Moore, David A. , Larsimont, Denis , Dillon, Deborah , Broeckx, Glenn , Bairi, Khalid El , Cimino‐Mathews, Ashley , Adams, Sylvia , Liu, S, Loibl, Sibylle , Chen, I‐Chun , Juco, Jonathan, Blackley, Elizabeth F. , Demaria, Sandra , Leon‐Ferre, Roberto A. , Zardavas, Dimitrios, Emancipator, Kenneth , Ely, Scott , Loi, Sherene , Salgado, Roberto , Group, International Immuno‐Oncology Biomarker Working, Cree, Ian , Haynes, Harry R , Balancin, Marcelo , Ehinger, Anna , Lazar, Alexander J , Broeckx, Glenn , El Bairi, Khalid , Leon-Ferre, Roberto, Gonzalez-Ericsson, Paula I , Bellizzi, Andrew M , Symmans, W Fraser , Loi, Sherene , Pruneri, Giancarlo , Rimm, David , Carter, Jodi , Sua, Luz Fernanda , Nielsen, Torsten O. , Fox, Stephen B. , Bartlett, John MS, Peeters, Dieter J. E. , Dieci, Maria Vittoria , Vincent‐Salomon, Anne , Balko, Justin M. , Badve, Sunil , Penault-Llorca, Frederique Madeleine , Lazar, Alexander J. , Lien, Huang‐Chun , Goetz, Matthew P. , Harbeck, Nadia , Sotiriou, Christos P. , Lakhani, Sunil R. , Denkert, Carsten , Gluz, Oleg , Sanders, Melinda E. , Group, International Immuno‐Oncology Biomarker Working
The Journal of Pathology | March 4, 2020 | Volume: 250 | Issue: 5 | Pages: 667-684
AbstractImmune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now the standard of care in oncology across several hematologic and solid tumor types, including triple negative breast cancer (TNBC). Patients with metastatic or locally advanced TNBC with PD‐L1 expression on immune cells occupying ≥1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab‐paclitaxel. However, concerns regarding variability between immunohistochemical PD‐L1 assay performance and inter‐reader reproducibility have been raised. High tumor‐infiltrating lymphocytes (TILs) have also been associated with response to PD‐1/PD‐L1 inhibitors in patients with breast cancer (BC). TILs can be easily assessed on hematoxylin and eosin–stained slides and have shown reliable inter‐reader reproducibility. As an established prognostic factor in early stage TNBC, TILs are soon anticipated to be reported in daily practice in many pathology laboratories worldwide. Because TILs and PD‐L1 are parts of an immunological spectrum in BC, we propose the systematic implementation of combined PD‐L1 and TIL analyses as a more comprehensive immuno‐oncological biomarker for patient selection for PD‐1/PD‐L1 inhibition‐based therapy in patients with BC. Although practical and regulatory considerations differ by jurisdiction, the pathology community has the responsibility to patients to implement assays that lead to optimal patient selection. We propose herewith a risk‐management framework that may help mitigate the risks of suboptimal patient selection for immuno‐therapeutic approaches in clinical trials and daily practice based on combined TILs/PD‐L1 assessment in BC. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.